(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau
(43) International publication date
20 June 2002 (20.06.2002)

(10) International publication number
WO 02/47660 A1

PCT

(51) International patent classification[7]: A61K 9/08, 47/12, 47/40

(21) International application number: PCT/FR01/03903

(22) International filing date: 10 December 2001 (10.12.2001)

(25) Language of filing: French

(26) Language of publication: French

(30) Data relating to the priority:
00/16,071 11 December 2000 (11.12.2000) FR

(71) Applicant *(for all designated States except US)*: SANOFI-SYNTHELABO [FR/FR]; 174 Avenue de France, 75013 Paris (FR).

(72) Inventors; and
(75) Inventors/Applicants *(US only)*: BOURRIAGUE-SEVE, Frédérique [FR/FR]; Le Village, F-34190 Ferrieres les Verreries (FR). BREUL, Thierry [FR/FR]; 118, avenue F. de Lesseps, F-34110 Frontignan (FR).

(74) Representative: THOURET-LEMAITRE, Elisabeth; Sanofi-Synthelabo, 174 avenue de France, F-75013 Paris (FR).

(81) Designated states *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ. EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX. MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated states *(regional)*: ARIPO Patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU. MC, NL, PT, SE, TR), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
- *With the International Search Report.*
- *Before expiry of the period provided for amending the claims, will be republished if such amendments are received.*

For an explanation of the two-letter codes and the other abbreviations, reference is made to the explanations ("Guidance Notes on Codes and Abbreviations") at the beginning of each regular edition of the PCT Gazette.



G00002

As printed

(54) Title: PHARMACEUTICAL DRONEDARONE COMPOSITION FOR PARENTERAL ADMINISTRATION

(54) Titre : COMPOSITION PHARMACEUTIQUE DE DRONEDARONE POUR ADMINISTRATION PARENTERALE

(57) Abstract: The invention concerns a pharmaceutical composition for parenteral administration, characterised in that it comprises. dronedarone or one of its pharmaceutically acceptable salts as active principle; a physiologically acceptable buffer solution capable of maintaining the pH of the composition between 3 and 5, a physiologically acceptable water-soluble β-cyclodextrin derivative.

(57) Abrégé : L'invention a pour objet une composition pharmaceutique pour administration parentérale, caractérisée en ce qu'elle comprend la dronédarone ou un de ses sels pharmaceutiquement acceptables en tant que principe actif; une solution tampon physiologiquement acceptable capable de maintenir le pH de la composition entre 3 et 5; un dérivé hydrosoluble de β-cyclodextrine physiologiquement acceptable.

WO 02/47660 A1

